• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    11/14/24 3:33:34 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VSTM alert in real time by email
    SC 13G/A 1 ea0221047-13ga2soleus3_veras.htm AMENDMENT NO. 2 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)*

     

    VERASTEM, INC.

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    92337C203

    (CUSIP Number)

     

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     


     

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity Fund III, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,333,332 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,333,332 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,333,332 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus Private Equity Fund III, L.P. (“Soleus PE”). Soleus Private Equity GP III, LLC (“Soleus PE GP”) is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management, L.P. (“Soleus Capital Management”) is the investment manager for Soleus PE and for Soleus Capital Master Fund, L.P. (“Master Fund”), and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the filing of this report shall not be deemed an admission that any of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management or Soleus GP, LLC is the beneficial owner of such shares for any other purpose.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of Verastem, Inc. (the “Issuer”) at an initial exercise price of $3.50 per share.

      

    (3) This percentage is calculated based upon 44,506,526 shares of the common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Issuer’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2024 that was filed with the Securities and Exchange Commission on November 6, 2024 (the “Form 10-Q”).

     

    2

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Private Equity GP III, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,333,332 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,333,332 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,333,332 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management or Soleus GP, LLC is the beneficial owner of such shares for any other purpose.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of the Issuer at an initial exercise price of $3.50 per share.

      

    (3) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    3

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus PE GP III, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    2,333,332 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    2,333,332 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,333,332 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.1% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus PE. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC. Each of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management and Soleus GP, LLC disclaims beneficial ownership of these shares held by Soleus PE other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Mr. Levy, Soleus PE GP III, LLC, Soleus PE GP, Soleus Capital Management or Soleus GP, LLC is the beneficial owner of such shares for any other purpose.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of the Issuer at an initial exercise price of $3.50 per share.

     

    (3) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    4

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Master Fund, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Cayman Islands

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,661,297 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,661,297 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,661,297 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    FI

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    5

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,661,297 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,661,297 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,661,297 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    6

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Group, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    1,661,297 (1)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    1,661,297 (1)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    1,661,297 (1)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    3.7% (2)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Master Fund. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC. Each of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held by Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus Capital Group, LLC, Soleus Capital, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.

     

    (2) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    7

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus Capital Management, L.P.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,994,629 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,994,629 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,994,629 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.7% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    PN

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, Soleus Capital Group, LLC and Soleus GP, LLC. Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of the Issuer at an initial exercise price of $3.50 per share.

     

    (3) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    8

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Soleus GP, LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,994,629 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,994,629 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,994,629 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.7% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    OO

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, Soleus Capital Group, LLC and Soleus GP, LLC. Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund, and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of the Issuer at an initial exercise price of $3.50 per share.

     

    (3) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    9

     

    CUSIP NO. 92337C203

     

    1

    NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

     

    Guy Levy

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

     

    (a) ☐ (b) ☐

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States

    NUMBER OF
    SHARES BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH:
    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    3,994,629 (1)(2)

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    3,994,629 (1)(2)

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    3,994,629 (1)(2)

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

     

    ☐

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    8.7% (3)

    12

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

     

    IN

     

    FOOTNOTES

     

    (1) The shares reported in this row are held directly by Soleus PE and by Master Fund. Soleus PE GP is the sole general partner of Soleus PE, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus Capital Management is the investment manager for Soleus PE, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Soleus Capital, LLC is the sole general partner of Master Fund, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital Management is the investment manager for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. Guy Levy is the sole managing member of each of Soleus PE GP III, LLC, Soleus Capital Group, LLC and Soleus GP, LLC. Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund, and this report shall not be deemed an admission that he is the beneficial owner of such shares for purposes of Section 13(d) of the Exchange Act, or for any other purpose, except to the extent of his pecuniary interest therein.
       
    (2) Includes presently exercisable warrants to purchase up to 1,166,666 shares of the common stock of the Issuer at an initial exercise price of $3.50 per share.

     

    (3) This percentage is calculated based upon 44,506,526 shares of common stock of the Issuer outstanding as of November 5, 2024, as set forth on the cover of the Form 10-Q.

     

    10

     

    Item 1.

     

      (a) Name of Issuer

     

    Verastem, Inc.

     

      (b) Address of Issuer’s Principal Executive Offices

     

    117 Kendrick Street, Suite 500

    Needham, MA 02494

     

    Item 2.

     

      (a) Name of Person(s) Filing

     

    Soleus Private Equity GP III, LLC

    Soleus Private Equity Fund III, L.P.

    Soleus PE GP III, LLC

    Soleus Capital Master Fund, L.P.

    Soleus Capital, LLC

    Soleus Capital Group, LLC

    Soleus Capital Management, L.P.

    Soleus GP, LLC

    Guy Levy

     

      (b) Address of Principal Business Office or, if none, Residence

     

    Soleus Private Equity GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Private Equity Fund III, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus PE GP III, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Master Fund, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Group, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus Capital Management, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Soleus GP, LLC

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    Guy Levy

    c/o Soleus Capital Management, L.P.

    104 Field Point Road, 2nd Floor

    Greenwich, CT 06830

     

    11

      

      (c) Citizenship

     

    Soleus Private Equity GP III, LLC – Delaware

    Soleus Private Equity Fund III, L.P. – Delaware

    Soleus PE GP III, LLC – Delaware

    Soleus Capital Master Fund, L.P. – Cayman Islands

    Soleus Capital, LLC – Delaware

    Soleus Capital Group, LLC – Delaware

    Soleus Capital Management, L.P. – Delaware

    Soleus GP, LLC – Delaware

    Guy Levy – United States

     

      (d) Title of Class of Securities

     

    Common Stock, $0.0001 par value per share

     

      (e) CUSIP Number

     

    92337C203

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
         
    (b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
         
    (c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. ☐78c).
         
    (d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
         
    (e) ☐ An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
         
    (f) ☐ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
         
    (g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
         
    (h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
         
    (i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
         
    (j) ☐ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).
         
    (k) ☐ Group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:

     

    12

     

    Item 4. Ownership.

     

    The information required by this item with respect to reach reporting person is set forth in rows 5 – 11 on the cover pages to this Schedule 13G.

     

    As noted on the cover pages of this Schedule 13G, Soleus PE GP III, LLC is the sole manager of Soleus PE GP, Soleus PE GP is the sole general partner of Soleus PE, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. As the sole managing member of each of Soleus PE GP III, LLC and of Soleus GP, LLC, Guy Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held directly by Soleus PE.

     

    As noted on the cover pages of this Schedule 13G, Soleus Capital Group, LLC is the sole managing member of Soleus Capital, LLC, Soleus Capital LLC is the sole general partner of Master Fund, Soleus Capital Management is the investment manager for Soleus PE and for Master Fund, and Soleus GP, LLC is the sole general partner of Soleus Capital Management. As the sole managing member of each of Soleus Capital Group, LLC and of Soleus GP, LLC, Mr. Levy may be deemed to have shared power to vote or direct the vote and to dispose or to direct the disposition of the securities held directly by Master Fund.

     

    Each of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC and Mr. Levy disclaims beneficial ownership of these shares held directly by Soleus PE and Master Fund other than for the purpose of determining their obligations under Section 13(d) of the Exchange Act, and the filing of this report shall not be deemed an admission that any of Soleus PE GP, Soleus PE GP III, LLC, Soleus Capital, LLC, Soleus Capital Group, LLC, Soleus Capital Management, Soleus GP, LLC or Mr. Levy is the beneficial owner of such shares for any other purpose. 

     

    Item 5. Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10. Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose, or with the effect, of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    13

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Date: November 14, 2024 Soleus Private Equity Fund III, L.P.
       
      By: Soleus Private Equity GP III, LLC, its General Partner
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Private Equity GP III, LLC
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus PE GP III, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member

     

    14

     

    Date: November 14, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Management, L.P.
       
      By:  Soleus GP, LLC, its General Partner
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus GP, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 /s/ Guy Levy
      Name: Guy Levy

     

    Footnotes:

     

    Attention: Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)

     

    15

     

    EXHIBIT 99.A

     

    EXHIBIT A

    JOINT FILING AGREEMENT

     

    Soleus Private Equity GP III, LLC, a Delaware limited liability company, Soleus Private Equity Fund III, L.P., a Delaware limited partnership, Soleus PE GP III, LLC, a Delaware limited liability company, Soleus Capital Master Fund, L.P., a Cayman Islands exempted limited partnership, Soleus Capital, LLC, a Delaware limited liability company, Soleus Capital Group, LLC, a Delaware limited liability company, Soleus Capital Management, L.P., a Delaware limited partnership, Soleus GP, LLC, a Delaware limited liability company, and Guy Levy, an individual, hereby agree to file jointly the statement on Schedule 13G to which this Joint Filing Agreement is attached, and any amendments thereto which may be deemed necessary, pursuant to Regulation 13D-G under the Securities Exchange Act of 1934, as amended.

     

    It is understood and agreed that each of the parties hereto is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein, but such party is not responsible for the completeness or accuracy of information concerning the other party unless such party knows or has reason to believe that such information is inaccurate.

     

    It is understood and agreed that a copy of this Agreement shall be attached as an exhibit to the statement on Schedule 13G, and any amendments hereto, filed on behalf of each of the parties hereto.

     

    Date: November 14, 2024 Soleus Private Equity Fund III, L.P.
       
      By: Soleus Private Equity GP III, LLC, its General Partner
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Private Equity GP III, LLC
       
      By: Soleus PE GP III, LLC, its Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus PE GP III, LLC
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Master Fund, L.P.
       
      By: Soleus Capital, LLC, its General Partner
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital, LLC
       
      By: Soleus Capital Group, LLC, its Managing Manager
       
      By: /s/ Guy Levy
      Name: Guy Levy
      Title: Managing Member

     

     

     

     
    Date: November 14, 2024 Soleus Capital Group, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus Capital Management, L.P.
       
      By:  Soleus GP, LLC, its General Partner
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 Soleus GP, LLC
       
      By: /s/ Guy Levy
      Name:  Guy Levy
      Title: Managing Member
       
    Date: November 14, 2024 /s/ Guy Levy
      Name: Guy Levy

     

     

     

     

     

    Get the next $VSTM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VSTM

    DatePrice TargetRatingAnalyst
    4/10/2025$15.00Buy
    Jefferies
    3/24/2025$7.00 → $10.00Buy
    H.C. Wainwright
    12/31/2024$13.00 → $20.00Buy
    BTIG Research
    9/30/2024$13.00Buy
    Guggenheim
    11/21/2023$27.00Buy
    BTIG Research
    9/27/2023$21.00Buy
    B. Riley Securities
    6/15/2023$24.00 → $36.00Neutral → Buy
    Mizuho
    9/7/2022$6.00Buy
    Alliance Global Partners
    More analyst ratings

    $VSTM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Rowinsky Eric K bought $7,680 worth of shares (2,000 units at $3.84) (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    1/24/24 4:00:39 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    SEC Filings

    View All

    SEC Form EFFECT filed by Verastem Inc.

    EFFECT - Verastem, Inc. (0001526119) (Filer)

    8/18/25 12:15:32 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.

    SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)

    8/14/25 5:56:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Verastem Inc.

    SCHEDULE 13G/A - Verastem, Inc. (0001526119) (Subject)

    8/14/25 8:13:23 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer

    GFH375 demonstrated an overall response rate (ORR) of 68.8% in non-small cell lung cancer (NSCLC) at the recommended Phase 2 dose of 600 mg QD GFH375 demonstrated an ORR of 57.7% in efficacy evaluable patients with NSCLC across all dose levels Mini oral presentation on Sunday, September 7, 2025 from 12:00 to 1:15 pm (CEST) Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK-pathway-driven cancers, today announced positive, updated safety and efficacy data and late-breaking presentation details of partner GenFleet Therapeutics' Phase 1/2 study in China of GFH375, an oral KRAS G12D (ON/OFF) inhibitor, known as VS-7

    8/13/25 4:29:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for

    8/7/25 4:05:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv

    7/29/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Paterson Dan sold $7,739 worth of shares (1,332 units at $5.81), decreasing direct ownership by 0.30% to 442,507 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    8/6/25 8:38:35 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President and CEO Paterson Dan sold $91,355 worth of shares (17,808 units at $5.13), decreasing direct ownership by 4% to 443,839 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    6/24/25 4:39:08 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Calkins Daniel sold $21,202 worth of shares (4,135 units at $5.13), decreasing direct ownership by 4% to 109,920 units (SEC Form 4)

    4 - Verastem, Inc. (0001526119) (Issuer)

    6/24/25 4:37:26 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Leadership Updates

    Live Leadership Updates

    View All

    Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

    Avutometinib plus defactinib granted priority review by FDA in December 2024, under the accelerated approval pathway, for KRAS mutant recurrent LGSOC; PDUFA action date set for June 30, 2025 Filed an investigational new drug application in the U.S. for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor RAMP 205 trial in 1L metastatic pancreatic cancer continues to progress with an additional dose cohort added and enrollment across all dose-level cohorts on track to complete in Q1 Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma $151.3 million including debt refinancing and equity issuance with Oberland, and equity issuance under at-the-market

    3/20/25 4:01:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology Names Matthew E. Ros as Chief Operating Officer

    New executive leadership supports the company's transition to a fully integrated commercial-stage organization in a year of transformative growth with a potential new product launch in mid-2025. Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the appointment of Matthew E. Ros as chief operating officer. In his role, Mr. Ros will report to Dan Paterson, president and chief executive officer, and will serve on the company's executive leadership team. "We are thrilled to welcome Matt to Verastem Oncology at an important time as we prepare for a mid-2025 product launch and th

    1/15/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Applied Therapeutics Appoints John H. Johnson as Executive Chairman

    Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ:APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr. Shoshana Shendelman has stepped down as Chair and CEO; andLes Funtleyder, Applied Therapeutics' Chief Financial Officer, has been named Interim Chief Executive Officer. Mr. John

    12/20/24 7:00:00 AM ET
    $APLT
    $RVPH
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Jefferies initiated coverage on Verastem with a new price target

    Jefferies initiated coverage of Verastem with a rating of Buy and set a new price target of $15.00

    4/10/25 12:44:18 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright reiterated coverage on Verastem with a new price target

    H.C. Wainwright reiterated coverage of Verastem with a rating of Buy and set a new price target of $10.00 from $7.00 previously

    3/24/25 7:46:47 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research reiterated coverage on Verastem with a new price target

    BTIG Research reiterated coverage of Verastem with a rating of Buy and set a new price target of $20.00 from $13.00 previously

    12/31/24 7:57:33 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 6:25:40 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Verastem Inc.

    SC 13G/A - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:38:53 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Verastem Inc.

    SC 13G - Verastem, Inc. (0001526119) (Subject)

    11/14/24 4:36:17 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VSTM
    Financials

    Live finance-specific insights

    View All

    Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates

    Achieved AVMAPKI™ FAKZYNJA™ CO-PACK net product revenue of $2.1 million in the first six weeks of launch First patient dosed in the U.S. trial for VS-7375, an oral KRAS G12D (ON/OFF) inhibitor, in KRAS G12D advanced solid tumors Ended Q2 2025 with $164.3 million in cash and cash equivalents; with product revenue and exercise of cash warrants, Company has expected cash runway into the second half of 2026 Company to host a conference call and webcast today at 4:30 p.m. ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported financial results for

    8/7/25 4:05:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025

    Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at least 10 minutes prior to the event start time. A live audio webcast of the call, along with accompanying slides, will be available under "Events & Presentations" in the Investor section of the Company's website, https://inv

    7/29/25 7:30:00 AM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves the AVMAPKI™ FAKZYNJA™ Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer

    AVMAPKI plus FAKZYNJA to be commercially available by prescription as a convenient oral combination co-packaged together and will be known as "AVMAPKI FAKZYNJA CO-PACK" Accelerated approval, well ahead of the June 30, 2025 PDUFA action date, was based on the Phase 2 RAMP 201 study that demonstrated a 44% overall response rate in patients with KRAS mutant recurrent LGSOC Verastem to host investor conference call and webcast today at 2:30 pm ET Verastem Oncology (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the U.S. Food and Drug Administration (FDA) has approved AVMAPKI™ FAKZYNJA™ CO-

    5/8/25 1:17:00 PM ET
    $VSTM
    Biotechnology: Pharmaceutical Preparations
    Health Care